Fundraising Fox
Melbourne · Series A · 47 people tracked
Find your way into Brandon Capital
Sign up to see every warm intro you have to Brandon Capital
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Brandon Capital team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
Brandon Capital focuses on life science venture investing across the full spectrum, from early-stage seed through to expansion capital. The firm supports health and life science companies from proof-of-concept to commercialisation, aiming to develop next-generation medical innovations. It typically acts as a founding investor in its portfolio companies and partners with entrepreneurs for the long term, working collaboratively to commercialise their technology. Through successive funds and a co-investment arrangement with its investors, Brandon provides capacity to support advancing portfolio companies, seeking strong financial returns alongside better patient outcomes.
Source: firm website, verified Oct 17, 2026.
Team · 47 people
from the firm's website & public directories
Lead investor at Brandon Capital for the Mirugen investment.
Serves as Acting CEO and Chair of portfolio company Mirugen.
What they invest in
from 19 of 24 portfolio companiesBiotech ×18Healthtech ×14Medical Devices ×13Deep Tech ×3Digital Health ×3Longevity ×2Media & Entertainment ×2Impact & Social Good ×1
HQs:Australia×6United Kingdom×3United States×2Germany×1
Investments · 24 tracked
founders shown can be your intro pathBy year:2025 · 12024 · 32023 · 12022 · 32020 · 12018 · 12017 · 111 dated
Aravax is a clinical-stage biotechnology company developing next-generation immunotherapies to treat food allergies.
BiotechHealthtechMedical DevicesMelbourne, AU
Sara Prickett(Co-founder)in
Co-investorsBreakthrough VictoriaNovartis Venture FundTenmileUniSeed Pty Ltd.
Axelia Oncology is a biopharmaceutical company developing AXA-042, a selective immunological agent designed to activate innate immune responses against checkpoint-insensitive solid tumors.
BiotechHealthtechMedical DevicesMelbourne, AU
David Jackson(Founder (Laboratory research origin))Grant Mchlachlan(Chief Executive Officer)
Co-investorsStoic VCUniSeed Pty Ltd.
Azura Ophthalmics develops a new therapeutic class of ophthalmic keratolytics aimed at treating lid margin and ocular surface diseases and other underserved ophthalmic conditions.
BiotechHealthtechMedical Devices
Luba(Director of Pre-Clinical Development)
Co-investorsOrbiMed
CatalYm develops immunotherapies for solid tumors by neutralizing GDF-15, a factor cancer cells use to suppress immune responses and resist treatment.
BiotechDeep TechHealthtechMunich, DE
Jörg Wischhusen(Scientific Co-founder)Scott Clarke(Chief Executive Officer)inPeter Garcia(Chief Financial Officer)Sujata Rao(Chief Medical Officer)inStefan Ries(Chief Scientific Officer and Head of Munich Site)inAndrea Goddard(Chief Technical Officer)in
Co-investorsJeito CapitalBioqube VenturesForbionBayern KapitalBioGeneration VenturesCanaan Partners+2 more
George Medicines develops single-pill combination therapies for cardiometabolic diseases such as hypertension and diabetes, leveraging research from The George Institute for Global Health.
BiotechDigital HealthHealthtechMedical Devices
Mark Mallon(Chief Executive Officer)inProfessor Anthony Rodgers(Chief Medical Officer)Dr Karl Roberts(Chief Operating Officer)in
Co-investorsBrandon BioCatalystBrandon Capital Partners
NRG Therapeutics is a biotech company developing small-molecule drugs targeting the mitochondrial permeability transition pore (mPTP) for neurodegenerative diseases such as ALS and Parkinson's.
BiotechHealthtechLongevity
Neil Miller(CEO)inRichard Rutter(CSO)inGrant Hawthorne(COO)inClaus Sundgreen(Chief Medical Officer)inPaul Thompson(CDO)in
BoardJonathan Savidge(Independent Non Executive Chair)
Co-investorsCriteria Bio VenturesNovartis Venture FundSV Health InvestorsBritish Business BankDementia DiscoveryM Ventures+2 more
Pheon Therapeutics develops targeted oncology treatments, focusing on antibody-drug conjugates (ADCs) for cancer therapy.
BiotechHealthtechMedical Devices
Co-investorsAtlas VentureBiotechnology Value FundForbionLightspeed Venture PartnersResearch Corporation TechnologiesTCG Crossover
Amaroq Therapeutics develops first-in-class therapies targeting long non-coding RNAs (lncRNAs) implicated in oncology and other diseases.
Biotech
Co-investorsBooster Innovation FundCure Kids VenturesTenmileBrandon Capital Partners
AstronauTx is a biotechnology company focused on drug discovery and development for neurodegenerative and neuroinflammatory diseases, working across small molecules and biologics.
BiotechDeep TechHealthtechLongevityMedical Devices
Jane Rhodes(Chief Executive Officer)inMagnus Ivarsson(Chief Scientific Officer)inHannah Pearce(Chief Operating Officer)inMichelle L. Mellion(Chief Medical Officer)in
.jpg)
PartnerJonathan Tobin· solo GP
Co-investorsDementia Discovery FundMPM BioImpactNovartis Venture FundSV Health InvestorsUCL Technology FundAlbionVC
Biotech Dispatch is an online news publication covering the biotechnology, pharmaceutical, and medical technology industries, with a focus on Australian companies and developments.
BiotechMedia & Entertainment
BioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals.
BiotechMedia & EntertainmentMedical Devices
PartnerJonathan Tobin· solo GP
Co-investorsSound Bioventures
Brandon BioCatalyst funds biomedical development opportunities associated with its Member Institutes, offering investments ranging from AU$500,000 to AU$30 million across stages from proof-of-concept to late-stage technologies.
BiotechDeep TechDigital HealthHealthtechImpact & Social GoodMedical Devices
PartnerJonathan Tobin· solo GP
Co-investorsBrandon Capital Partners
ENA Respiratory develops and brings respiratory treatments to market across the US and other regions.
BiotechHealthtechMedical DevicesMelbourne, AU
Christophe Demaison(CEO)in
Co-investorsBrandon BioCatalystStoic VCUniSeed Pty Ltd.
Bristol Myers Squibb is a biopharmaceutical company that develops and delivers medicines across oncology, hematology, neuroscience, immunology, and cardiovascular disease areas.
BiotechHealthtechMedical DevicesNew York, US
PartnerJonathan Tobin· solo GP
Co-investorsKleiner PerkinsNew Enterprise Associates (NEA)Nextech InvestProspect Venture PartnersRho Capital PartnersRho Ventures+3 more
Myricx Bio is a biotech company developing antibody drug conjugates (ADCs) based on N-myristoyltransferases (NMT) inhibitors for cancer treatment.
BiotechMedical DevicesLondon, GB
Co-investorsBrandon Capital PartnersNovo HoldingsSofinnova PartnersAbingworth
Okogen is a clinical-stage ophthalmic pharmaceutical company developing a treatment for acute infectious conjunctivitis, covering both bacterial and viral forms.
BiotechHealthtechMedical DevicesPlano, US
Joshua Moriarty(Executive Officer, Director)inBrian Strem(Director, Promoter)Bradford Conlan(Director, Promoter)Eric J. Daniels(Executive Officer, Director, Promoter)Chris Smith(Director)Leighton Reid(Director)
Pathios Therapeutics is a drug discovery and development company working on small-molecule drugs that block the immune cell receptor GPR65, which senses the acidic tumor microenvironment, with a lead asset (PTT-4256) aimed at treating solid cancers.
BiotechHealthtechMedical DevicesOxford, GB
Alan Naylor(Founder)inStuart Hughes(Chief Scientific Officer)in
Co-investorsCanaan Partners
Perx develops a digital health platform that uses engagement and behavioral incentive techniques to help older patients, those with chronic conditions, and underserved populations adhere to their treatment plans and manage their health.
Digital HealthHealthtechSaaSAustralia / USA
Hugo Rourke(CEO & Co-founder)inScott(COO & Co-founder)
Co-investorsAirTree VenturesGiant LeapTenmileTractor VenturesWildwood Ventures
Biotechnology company enhancing vaccine performance with its HD-MAP high-density microarray skin-delivery platform, targeting infectious disease and oncology.
Co-investorsOneVenturesR&D Tax IncentiveTorrey Pines Investment
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
AdvancellAtox BioMirugenPheon TherapeuticsQuench Bio
Portfolio news
latest coverage across their companies
Myricx Bio · techfundingnews.com · Jul 6, 2026
Frequently asked questions
- How many investments has Brandon Capital made?
- Brandon Capital has 24 tracked investments, 1 of which have exited, including 1 dated in the last 24 months.
- What stage does Brandon Capital invest at?
- Brandon Capital invests at the Series A stage.
- What sectors does Brandon Capital focus on?
- Brandon Capital focuses on Biotech, Digital Health, Medical Devices.
- Where is Brandon Capital located?
- Brandon Capital is headquartered in Melbourne, AU.
- Who does Brandon Capital co-invest with?
- Brandon Capital most often shares deals with Novartis Venture Fund, Brandon Capital Partners, SV Health Investors, among 35 tracked co-investors.
- What size deals does Brandon Capital back?
- Across 6 deals with disclosed amounts, Brandon Capital has joined rounds of $18M – $120M (median $62.5M).
Co-investors · 11
Novartis Venture Fund is the corporate venture arm investing in life science companies, backing innovative drugs and treatments across various stages of growth.
Atlas Venture is a biotechnology-focused venture firm that creates and builds breakthrough life science companies, backing entrepreneurs to translate scientific research into new medicines.
Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.
Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.
BioGeneration Ventures is a European venture capital firm investing in early-stage biotech, medtech and life sciences companies developing novel therapeutics and medical technologies.
Novo Holdings is the investment arm of the Novo Nordisk Foundation and a leading life science investor that also manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity assets.
Bayern Kapital is a public venture capital and growth investor backing innovative Bavarian high-tech, deep tech and life sciences start-ups and scale-ups, acting as an anchor investor across multiple funding rounds.
Red Tree Venture Capital is a life sciences venture firm founded in 2020 by Heath Lukatch and Jennifer Cochran, investing in and building biopharma and life science companies with strong ties to West Coast academic and biopharma ecosystems.
Grotech Ventures is a venture capital firm that invests in and supports early- and growth-stage B2B software companies located outside of Silicon Valley.
A healthcare-focused investment firm that partners with healthcare entrepreneurs to build novel technologies and therapeutics.
Mission BioCapital provides early-stage capital and shared lab space to life science entrepreneurs, supporting companies from idea through clinic and exit.
Firms observed investing alongside Brandon Capital, from public investor directories. Shared companies are the overlap with Brandon Capital's recorded portfolio.
Similar investors
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.
US Venture Partners (USVP) is an early-stage venture capital firm investing in information technology and healthcare companies, with four decades of investing experience.
Frist Cressey Ventures (FCV) is a venture capital firm focused on transforming healthcare and improving lives, offering portfolio companies strategic support alongside capital.
MedMountain Ventures (MMV) is a physician-led, early-stage healthcare venture capital firm founded by board-certified physicians and healthcare operators that backs companies improving patient outcomes and transforming care delivery.
Sandbox Industries is an investment firm focused on healthcare and insurance, partnering with industry stakeholders as strategic limited partners alongside financial investors and its portfolio companies.